Titan Pharmaceuticals Inc. held its 2025 Annual Meeting of Stockholders on June 16, 2025. During the meeting, several proposals were put to a vote. The election of five directors was approved. The issuance of more than 20% of the company's common stock pursuant to a private placement transaction was approved. An amendment to the company's 2015 Omnibus Equity Incentive Plan to increase the total number of shares authorized for issuance and extend the term by an additional five years was also approved. Additionally, the ratification of Enrome LLP as the company's independent auditors for the fiscal year ending December 31, 2025, was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.